Poster
38
(#38) Impact of Antidepressants on the Longitudinal Evolution of Major Depressive Disorder Symptomatology
Psych Congress 2025
Abstract: Background: Major depressive disorder (MDD) is often treated with antidepressants such as SSRIs, bupropion, and vortioxetine, but their effectiveness for MDD symptoms varies over time. This real-world study assessed the longitudinal outcomes of individuals taking these commonly used antidepressants.
Methods: Adults with MDD taking antidepressants were eligible. Online interviews were performed using the Ad-Infer EVAL system, a tool designed for positive and differential AI diagnosis assessment, and data collection. Initial interviews (W1) were conducted in May-October 2024, and follow-up interviews (W2) in September 2024-March 2025; 56.4% of the initial sample participated in W2. The final sample, after adjusting for age, sex, and physician specialty, included 75 participants taking fluoxetine or paroxetine (GR1), 44 taking bupropion (GR2), and 40 taking vortioxetine (GR3).
Results: The majority of participants were women (GR1, 81.0%; GR2, 54.5%; GR3, 77.5%). By W2, MDD episode prevalence decreased by 14.0% in GR1, 30.1% in GR2, and 20.0% in GR3, and recurrences were higher in GR1 (87.0%) than GR2 (50.0%) and GR3 (51.5%; P 0.01 vs GR1). Significant differences in reported symptoms at W1 vs W2 (all P 0.01) included cognitive impairment in GR1 (51.4% vs 28.6%) and GR3 (37.5% vs 20.0%); sleep difficulties in GR1 (36.2% vs 23.8%) and GR3 (37.5% vs 20.0%); suicidal attempts in GR1 (22.7% vs 8.6%) and GR3 (27.5% vs 7.5%); and sexual disinterest in GR1 (18.6% vs 54.8%) and GR2 (25.0% vs 7.1%).
Conclusions: These findings highlight important outcome differences with SSRIs (fluoxetine/paroxetine), bupropion, and vortioxetine and may support informed, personalized treatment plans.
Short Description: Antidepressants such as SSRIs, bupropion, and vortioxetine are often prescribed for major depressive disorder (MDD), but can vary in effectiveness for specific symptoms. This US-based, real-world study in adults with MDD taking antidepressants was conducted via 2 online interviews per participant, powered by an AI-driven platform, that focused on clinical outcomes. Final study results showed significant differences between antidepressants in MDD recurrence rates and in some MDD symptoms by the second interview.
Name of Sponsoring Organization(s): Takeda Pharmaceuticals U.S.A., Inc.
Methods: Adults with MDD taking antidepressants were eligible. Online interviews were performed using the Ad-Infer EVAL system, a tool designed for positive and differential AI diagnosis assessment, and data collection. Initial interviews (W1) were conducted in May-October 2024, and follow-up interviews (W2) in September 2024-March 2025; 56.4% of the initial sample participated in W2. The final sample, after adjusting for age, sex, and physician specialty, included 75 participants taking fluoxetine or paroxetine (GR1), 44 taking bupropion (GR2), and 40 taking vortioxetine (GR3).
Results: The majority of participants were women (GR1, 81.0%; GR2, 54.5%; GR3, 77.5%). By W2, MDD episode prevalence decreased by 14.0% in GR1, 30.1% in GR2, and 20.0% in GR3, and recurrences were higher in GR1 (87.0%) than GR2 (50.0%) and GR3 (51.5%; P 0.01 vs GR1). Significant differences in reported symptoms at W1 vs W2 (all P 0.01) included cognitive impairment in GR1 (51.4% vs 28.6%) and GR3 (37.5% vs 20.0%); sleep difficulties in GR1 (36.2% vs 23.8%) and GR3 (37.5% vs 20.0%); suicidal attempts in GR1 (22.7% vs 8.6%) and GR3 (27.5% vs 7.5%); and sexual disinterest in GR1 (18.6% vs 54.8%) and GR2 (25.0% vs 7.1%).
Conclusions: These findings highlight important outcome differences with SSRIs (fluoxetine/paroxetine), bupropion, and vortioxetine and may support informed, personalized treatment plans.
Short Description: Antidepressants such as SSRIs, bupropion, and vortioxetine are often prescribed for major depressive disorder (MDD), but can vary in effectiveness for specific symptoms. This US-based, real-world study in adults with MDD taking antidepressants was conducted via 2 online interviews per participant, powered by an AI-driven platform, that focused on clinical outcomes. Final study results showed significant differences between antidepressants in MDD recurrence rates and in some MDD symptoms by the second interview.
Name of Sponsoring Organization(s): Takeda Pharmaceuticals U.S.A., Inc.
